

The Emerging Role of Natural Killer Cells in Innate and Adaptive Immunity

Eun-Mi Kim², Chang-Bo Ko¹, Pyung-Keun Myung², Daeho Cho³, Inpyo Choi⁴, and Hyung-Sik Kang¹

¹*School of Biological Sciences and Technology, Hormone Research Center, Chonnam National University, Gwangju,*

²*Department of Pharmacy & Research Center for Transgenic cloned Pig, Chungnam National University, Daejeon,*

³*Department of Life Science, Sookmyung Women's University, Seoul,* ⁴*Laboratory of Immunology, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.*

ABSTRACT

In the early host defense system, effector function of natural killer (NK) cells results in natural killing against target cells such as microbe-infected, malignant, and certain allogenic cells without prior stimulation. NK cell cytotoxicity is selectively regulated by homeostatic prevalence between a repertoire of both activating and inhibitory receptors, and the discrimination of untransformed cells is achieved by recognition of major histocompatibility complex (MHC) class I alleles through inhibitory signals. Although it is well known that the bipotential T/NK progenitors are derived from the common precursor, functional mechanisms in terms of the development of NK cells remain to be further investigated. NK cells are mainly involved in innate immunity, but recent studies have been reported that they also play a critical role in adaptive immune responses through interaction with dendritic cells (DC). This interaction will provide effector functions and development of NK cells, and elucidation of its precise mechanism may lead to therapeutic strategies for effective treatment of several immune diseases. (**Immune Network 2004;4(4):205-215**)

Key Words: Natural killer cells, innate immunity, adaptive immunity, development, function, NK receptors, tumor, major histocompatibility complex, dendritic cells

Introduction

Natural killer (NK) cells play a central role in early host defense via interaction of activating receptors with their ligands on virus-infected cells, tumor cells, and some normal allogenic cells in the absence of prior sensitization (1). NK cells have an ability to discriminate between normal cells and cells lacking the expression of MHC class I molecules due to the recognition through NK inhibitory receptors that specific for major histocompatibility complex (MHC) class I molecules. Their morphological characteristic showed a large granular lymphocyte (LGL)-like morphology based on the presence of densely staining azurophilic granules in their cytoplasm. In general, phenotype of NK cells is characterized by the expression of the

CD56 and CD16 (in human), NKR-P1C (NK1.1 in mouse, CD161 in human), DX5, Ly49 (in mouse; these are restricted to certain mouse strains) surface antigen and the lack of CD3. They comprise approximately 10 to 20% in normal peripheral blood lymphocytes, 15 to 25% in liver lymphocytes, and 1 to 5% in spleen lymphocytes. The majority (comprising 90% of total NK cells) of human NK cells have low-density expression of CD56 (CD56^{dim}, more cytotoxic) and express high levels of Fcγreceptor III (FcγRIII, CD16), whereas ~10% of NK cells are CD56^{bright}CD16^{dim} or CD56^{bright}CD16⁻ (2,3). Whereas effector function of NK cells can be stimulated by cytokines including interleukin-2 (IL-2), IL-12, IL-15, IL-18, IL-21, type I interferon (IFNαβ) in combination with differential engagement of cell surface receptors, they produce immunoregulatory cytokines such as IFN-γ, IL-5, IL-10, IL-13, tumor necrosis factor (TNFα), and granulocyte-macrophage colony-stimulating factor (GM-CSF), as well as a number of

Correspondence to: Hyung-Sik Kang, School of Biological Sciences and Technology, Hormone Research Center, Chonnam National University, Gwangju 500-757, Korea. (Tel) 82-62-530-2195, (Fax) 82-62-530-0315, (E-mail) kanghs@jnu.ac.kr

chemokines following interaction of NK receptors with their ligands (4) NK cells are also able to induce spontaneous cytolytic activity independent on MHC class I antigen-specific recognition to kill target cells ('missing self' hypothesis) contrary to cytotoxic T lymphocytes (CTL) (5). This means that signaling through inhibitory NK receptor can protect from NK cell-mediated cytotoxicity in healthy cells expressing normal levels of MHC class I molecules. Therefore, down-regulated MHC class I expression, which can be occurred by malignant transformation or virus infection of target cells may give rise to NK cell-mediated killing (6). They also mediate antibody-dependent cellular cytotoxicity (ADCC) through FcγRIII (CD16), a receptor molecule that specifically binds the Fc portion of an antibody (7). In addition to functional roles of NK cells in the early defense to infection, NK cells are capable of the regulation of adaptive immune responses by inducing T cell-mediated memory (8), and B cell-mediated autoimmunity (9).

NK cell development by cytokines and transcription factors

Although NK cells have been well known to be derived from pluripotent hematopoietic stem cells (HSCs) (10,11), the ontogeny of NK cells has not been fully understood yet. HSCs ($\text{Lin}^- \text{CD34}^+$ in human, $\text{Lin}^- \text{c-kit}^+ \text{Sca2}^+$ in mouse) from fetal thymus, fetal liver, umbilical cord blood, and adult bone marrow (BM) have a potential to develop into the common T/NK bipotent progenitors (11,12), which are committed to NK cell precursors (pNKs) upon *in vitro* culture in combination with IL-7, stem cell factor (SCF), and Fms-like tyrosine kinase 3 ligand (flt3L) (13)(Fig. 1). Even though pNK cells are widely distributed in the BM, fetal thymus, blood, spleen, and liver, they are absent of both cytolytic activity as well as ability to produce large amounts of IFN- γ , but express CD122 ($\text{IL-2/15R}\beta^+$). In addition, low levels of NKp46, NKp30 and 2B4 are also expressed in pNK cells before the expression of CD94/NKG2A and KIRs, and their appearance correlated with the




Figure 1. *In vitro* model of NK cell development from hematopoietic stem cells (HSCs). Bipotent T/NK progenitors (T/NKP) derived from HSCs ($\text{c-kit}^+ \text{Sca-1}^+$) have originated in common lymphoid progenitors (CLP) upon *in vitro* culture in combination with FLT3L, IL-7, and SCF. From T/NKP, further cultures of NK cell precursors (pNK; CD122^+) with IL-15 alone arise to immature NK cells (CD2^+ and CD161^+ in human, NK1.1^+ in mouse), which can differentiate sequentially to pseudomature cytolytic NK cells (CD94^+ , $\text{CD56}^+ \text{CD161}^+ \text{KIR}^-$ in human and $\text{NK1.1}^+ \text{DX5}^+ \text{Ly49}^-$ in mouse). The interaction of pNK cells with stromal cells can generate mature NK cells (KIR^+ in human, and Ly49^+ in mouse) with cytolytic activity. At differential stages of cells during NK cell development, the expression of transcription factors and developmental cell surface markers is highlighted in color.

acquisition of cytolytic activity (14). When pNK cells

(CD56⁺CD122⁺CD34⁺ in human, CD122⁺ NK1.1⁺ DX5⁺ in mouse) are subsequently cultured in the presence of IL-15 or IL-2 alone, the cells are able to develop into immature NK cells (CD122⁺CD16^{lo} CD56⁺KIR⁺ in human, CD122⁺CD2⁺NK1.1⁺DX5⁺ Ly49⁺ in mouse). Prolonged culture of pNK cells with IL-15 alone can generate the pseudomature lytic NK cells (CD122⁺CD2⁺NK1.1⁺DX5⁺CD94/NKG2⁺ Ly49⁺), which have partial cytolytic activities. Several works have been shown that stromal cells provide both various cytokines and direct contact *via* cell surface receptors to developing NK cells, indicating that they are essential for the generation of lytic Ly49⁺ mature NK cells as well as the maturation of NK cells (15,16). Thus, high frequency of activated lytic Ly49⁺ mature NK cells (CD56⁺KIR⁺CD3⁺ in human, CD122⁺CD2⁺NK1.1⁺DX5⁺CD94/NKG2⁺ Ly49⁺ CD3⁺ in mouse) arises from the co-culture of pNK cells with stromal cells in the presence of IL-5 (13). At differential stages of NK cells during NK cell development, CD94, NKG2A, NKG2C and Ly49B were expressed at the early stages of development, and Ly 49G, Ly49C, Ly49I, orderly, and finally, Ly49A, D, E and F (17). After acquisition of these receptors, the developing NK cells acquire expression of several integrins in the order of α_c , DX5, and Mac-1 during the maturation process followed by intensive expansion of NK cells.

Interaction between NK cell progenitors and stromal cells is required for the development of NK cells as shown in the cases of lymphotoxin (LT)-deficient mice and interferon regulatory factor (IRF)-1-deficient mice (15,18,19). The number of NK cells is profoundly reduced in the spleen and BM from LT α ^{-/-} mice, and impaired NK cell effector functions (15). Administration of LT β R-Ig gives rise to a reduction of NK cell numbers, but adoptive transfer of wild type BM cells to LT α ^{-/-} mice did not restore splenic NK cells, suggesting that LT-dependent microenvironment is essential for NK cell development. However, treatments of IL-15 to BM cells from LT^{-/-} mice restore NK cell population. It indicates that LT delivers a unique signal for NK cell development, which is independent of IL-15. NK cell development is also found to be impaired in IL-2R β -deficient mice, characterized by a reduction in NK1.1⁺CD3⁺ cells in the peripheral circulation and an absence of NK cytotoxic activity *in vitro* (16,20).

In addition to cell surface receptors and cytokine signals, transcription factors are also indispensable for the development of NK cells. pNK cells express transcription factors such as PU.1, GATA3, Id2, and Ets-1. Deficiency of ikaros (21), PU.1 (22), and Id2 (23) causes reduced numbers of pNK cells in mice. In HSCs, transcription factors such as myeloblastosis

(myb) oncogene, forkhead-related transcription factor 1C, c-myc, and Oct 2b may play important roles in the regulation of development or proliferation of pNK cells. c-myc has been reported as a key molecule for the commitment of murine erythroleukemia cell development (24), and c-myb regulates terminal development of HSCs through the regulation of hematopoietic commitment and progenitor cell proliferation (25). In pNK cells, immune regulators such as Fc γ receptor, TNF receptor, IL-7 receptor, chemokine receptor, and CD36 seems to have critical roles in this stage. In mature NK cells, signaling molecules such as regulator of G protein signaling- γ (RGS- γ), lymphocyte-specific protein tyrosine kinase, Fyn proto-oncogene, and mitogen activated protein kinase 1 may deliver positive or negative signals for NK cell maturation. It has been reported that overexpression of Id2 in HSCs markedly enhanced NK development, whereas the generation of other immune cells was blocked (23). Expression of Id2 is known to be correlated with p-NK activity. NK cells from fetal thymus of Id2^{-/-} mice were markedly reduced, and pNK cells are completely missing, suggesting that Id2 is indispensable in thymic NK cell development, where it allows most probably restricts bipotent T/NK progenitors to the NK cell lineage. IRF-1 is also known to be necessary for the supporting NK cell development in the microenvironment, and IRF-1^{-/-} mice have severe NK cell deficiency (19). When BM cells from IRF-1^{-/-} mice are cultured in the presence of IL-15 during the lineage commitment of NK cells, and IL-15 gene expression is regulated by IRF-1. Adoptive transfer of BM cells of IRF-1^{-/-} mice to wild type mice resulted in the recovery of functional NK cells. Ikaros^{-/-} mice exhibit low levels of flt3 and c-kit (CD122) receptors, indicating that ikaros is also essential for pNK cell maturation (26). Also, Ets-1^{-/-} mice showed the reduced number of splenic NK cells and the defective cytolytic activity against NK cell targets *in vivo* and *in vitro* (27). Ets^{-/-} NK cells have normal levels of IL-2R- α and - γ . Addition of cytokines such as IL-2, IL-15, IL-12, and IL-18 did not restore cytolytic activity of NK cells from Ets^{-/-} mice. Mice deficient in PU.1, which is another member of the Ets family of transcription factors and regulates the expression of c-kit and IL-7 receptors, can generate functional NK cells from hematopoietic progenitors of PU.1^{-/-} fetal liver cells, but they show reduced pNK cell numbers in BM and spleen (22,28). These mice fail to proliferate in response to IL-2 and IL-12, and lack Ly49 antigens. Clonal Ly49A acquisition is regulated by T cell factor-1 (TCF-1) during NK cell development, and TCF-1^{-/-} mice show a selective reduction in Ly-49A expression (29,30). Mice that lack MEF, a member of the ETS family of

winged helix-turn-helix transcription factors, have a profound reduction in the number of NK and NKT cells (31). MEF^{-/-} NK cells are defective in cytotoxicity against tumor cell targets, and produce minimal amounts of both IFN- γ and perforin.

Recently, we have been reported that vitamin D₃ up-regulated protein 1 (VDUP1) is a stress-response gene which is up-regulated by 1,25 (OH)₂D₃ in tumor cells. VDUP1^{-/-} mice showed a profound reduction in the numbers of NK cells, and in NK cell activity. In the VDUP1^{-/-} mice, the expression of CD122 was reduced. Our data indicated that VDUP1 is also required for CD122 expression and NK cell maturation (32).

NK cell receptors and their ligands

NK cell effector functions are regulated by a balance between activating receptors and inhibitory receptors that interact with their ligands such as MHC class I or MHC class I-related molecules (non-classical MHC class I) on the target cells (33)(Table 1). These receptors are divided into two structural families: immunoglobulin superfamily (leukocyte inhibitory receptors, killer cell Ig-like receptors (KIR, CD158) and C-type lectin-like family (NKG2D, CD94/NKG2, lymphocyte antigen 49 (LY49)).

NK cell activating receptors are essential for the activation of NK cell effector functions, which results in either cytotoxicity and/or cytokine production. Natural cytotoxicity receptors (NCRs) consist of the receptor NKp30, NKp44, and NKp46, and all of which play a key role in NK-cell-mediated lysis of tumor cells upon signaling through the differential association with the adaptor molecules (DAP12, Fc γ , or CD3 ζ) (34,35). Indeed, mice that lack the cell surface adaptor molecules have defect in NK-mediated tumor cell killing (35). In contrast to other NCRs, the expression of NK p44 (DAP12/KARAP) is restricted only in IL-2-activated NK cells (36). MICA (MHC class I chain-related molecule) is known as a stress-inducible human nonclassical MHC class I molecule, and their receptor, NKG2D, is predominantly expressed on NK cells, $\gamma\delta^+$ T cells, CD8⁺ $\alpha\beta$ T cells (37). Activating signals are triggered by association of NKG2D homodimers with DAP10 or DAP12 transmembrane signaling adaptor molecule, which has an immunoreceptor tyrosine-based activating motif (ITAM) domain (38)(Fig. 2). Following receptor-ligand association, ITAM-containing adaptor molecules recruit src family kinases at the tyrosine residues (35). NKG2D/DAP10 receptor complex transmits activating signals through recruiting the p85 subunit of the phosphatidylinositol-3-kinase (PI3K)(39), leading to NK cell-mediated cytotoxicity against MICA-bearing tumors (39,40), whereas DAP12 can trigger Syk family protein tyrosine

Table 1. Activating and inhibitory receptors of NK cells

Receptor	Ligands	Function	Species
NKG2A	HLA-E/Q ^a -1 ^b	Inhibition	H, M
NKG2C	HLA-E/Q ^a -1 ^b	Activation	H, M
NKG2D	MICA/B, ULBPs (Human), Rac-1, H60 (mouse)	Activation	H, M
NKG2E	HLA-E/Qa-1b	Activation	H, M
NKp30 (NCR3)	Unknown	Activation	H
NKp44 (NCR2)	Unknown	Activation	H
NKp46 (NCR1)	Unknown	Activation	H, M
NKR-P1A	Unknown	Activation	H, M
NKR-P1B	Unknown	Inhibition	M
NKR-P1C	Unknown	Activation	M
NKR-P1D	Unknown	Inhibition	M
NKR-P1F	Unknown	Activation	M
Ly49A	H-2D	Inhibition	M
Ly49C	H-2D, H-2K	Activation	M
Ly49D	H-2D	Activation	M
Ly49E	Unknown	Inhibition	M
Ly49G	H-2D	Inhibition	M
Ly49H	MCMV m157	Activation	M
KIR2DL	HLA-C/G	Inhibition	H
KIR2DS	HLA-C	Activation	H
KIR3DL (CD158)	HLA-A, HLA-Bw4	Inhibition	H
CD2	CD58 (LFA-3 [†])	Activation	H, M
CD16	IgG	Activation	H, M
CD28	B7.1/B7.2	Activation	H, M
CD40L	CD40	Activation	H, M
CD226 (DNAM-1 [‡])	CD112 (Nectin-2), CD155 (PVR*)	Activation	H
CD244 (2B4)	CD48	Inhibition	H, M
ILT2	HLA-G	Inhibition	H
ILT4	HLA-F	Inhibition	H
P75/AIRM1	Sialylated sugars moieties	Inhibition	H

[†] LFA-3, lymphocyte function-associated antigen; [‡] DNAM, DNAX accessory molecule; *PVR, Polio virus receptor.

kinases. An association of Ly49H NK cell activating receptor with DAP12 triggers NK cell-mediated cytotoxicity and cytokine expression (41).

UL16-binding proteins (ULBPs), another NKG2D ligands, that are expressed on stressed, infected, or tumor cells bind to the human cytomegalovirus glycoprotein UL16 (42), and their engagements by NKG2D allow NK cells to kill target cells. It has been known that NK cell inhibitory receptors bind to the MHC class I ligands more strongly than the do activating receptors, suggesting that the balance between inhibitory and activating receptor signaling in favor of activation (43-45). Binding of NK cell inhibitory receptors with their ligands renders the target cells to be protected from NK cell-mediated cytotoxicity. Signaling *via* NK cell inhibitory receptors is usually




Figure 2. Interaction between NK cell receptors and their ligands. NK cell function is regulated by activating and inhibitory signaling. When NK cell inhibitory receptors bind their ligands (eg, HLA-E in human, and Qa-1 in mouse; classical or non-classical MHC class I molecules) on the surface of the target cells, ITIM domains in the cytoplasmic tails of the inhibitory receptors (NKG2 isoforms such as NKG2A and NKG2B heterodimerized with CD94 lectin-like receptor, Ly49A, and KIR2DL) on NK cells are phosphorylated at tyrosine residues. This phosphorylation induces the recruitment of Src homology 2 domain-containing protein tyrosine phosphatase-1 (SHP-1), leading to inhibitory signaling via the dephosphorylation of signaling molecules. The long isoform of NKG2D (NKG2DL) is predominantly expressed in resting NK cells, and associated with DNAX-activating protein of 10kDa (DAP10), while the expression of short isoform (NKG2DS) is upregulated in activated NK cells. Upon ligation, YNIM motifs of the DAP10 adaptor protein are phosphorylated, and the activation of phosphatidylinositol-3 kinase (PI3K) is induced. In contrast to NKG2D/DAP10 complexes, the phosphorylation is occurred in ITAM domains of DAP12 associated with the activating receptors (NKG2D, CD94-NKG2 isoforms, Ly49 isoforms, and KIR2DS) followed by the recruitment and activation of Syk or ZAP-70 protein tyrosine kinases capable of activating NK cells.

triggered by immunoreceptor tyrosine-based inhibitory motif (ITIM) domains in the cytoplasmic tails of these NK receptors. The phosphorylation of ITIM domain by ligand binding is capable of recruitment of src homology containing protein tyrosine phosphatases (SHPs) followed by blocking of NK effector functions (43,46). Studies in gene-disrupted mice have shown that disrupting interactions of KIR with their ligands on tumor cells *in vivo* may enhance antitumor responses mediated by both innate and adaptive immune effector cells (47). In addition, CD94-NKG2A com-

plex inhibits CD16-mediated NK cell cytotoxicity through ADCC in tumour cell lines (48).

NK cells that also express a number of co-stimulatory receptors including CD27, CD28/ICOS (inducible co-stimulator) and CD154 stimulate NK cell activation (37,49). The constitutive expression of CD27, a member of the TNF receptor superfamily, is up-regulated on IL-2-activated NK cells. CD27-mediated activation appears to play an important role in the NK cell-mediated innate immunity against virus-infected or transformed cells expressing its ligand (CD70)(50,49).

It has been reported that CD70 expression promoted the rejection of MHC class I-deficient tumor, which is mediated by NK cells and granule exocytosis-dependent mechanisms (8). Since the NK cell-mediated tumor rejection gives rise to the subsequent tumor-specific cytotoxic and T helper 1 (Th1) responses, these data raise the possibility that CD27-mediated activation by CD70 may be a conclusive evidence for the relation between the innate immunity and adaptive immunity. The murine NK cell-mediated cytotoxicity against tumor cells is dependent on interaction between CD28 and their ligands, CD80 (B7.1), but this interaction is not involved in triggering of human adult NK cells (51-53).

In addition to interactions between CD40L (CD154) and CD40, murine CD40 and CD86 (B7.2) trigger murine NK cell-mediated cytotoxicity against tumor cells, suggesting that they have ability to interact with receptors on NK cells other than CD40L and CD28, respectively (54,55). Since engagement of 2B4 (CD244) on NK-cell surfaces with specific antibodies or its ligand CD48 is capable of triggering lysis of target cells and interferon- γ secretion, 2B4 is originally known as an activating receptor, so that it may contribute to the NK cell effector functions. However, this is shown to function as an inhibitory receptor at early stages of NK cell development to prevent killing of normal autologous cells, rather than as an activating receptor (56). As a consequence, it is likely that its role is depend upon the interaction with NCRs, and remains inconclusive.

NK cell effector functions by cytokine regulation

Immunoregulatory cytokines including IFN- α , IFN- β , IL-2, IL-12, and IL-15 are able to stimulate the effector functions of resting NK cells, which represent activity for cytotoxicity, survival, and proliferation as well as innate immunity against virally infected cells and tumor cells (37,57,58). It is believed that IL-2, IL-12 and IL-15 may be useful for tumor immunotherapy (13,14). Long-term immunotherapy with low-dose IL-2 and IFN- α in patients with advanced renal cell carcinoma resulted in clinical response rates and survival probabilities that are similar to those obtained using higher doses of IL-2 (37). In human, CD56^{bright} NK cell subset also produces several cytokines including IFN- γ , TNF- α , TNF- β , IL-10 and GM-CSF (61), but CD56^{dim} NK cell subset do not produce these cytokines (2,4). Although immature NK cells can produce Th2 cytokines such as IL-5 and IL-13, the ability to produce Th2 cytokines is lost upon terminal development; instead, mature NK cells acquire ability to produce IFN- γ (62). IFN- γ has been demonstrated to stimulate adap-

tive immunity, antigen presentation by upregulating MHC class I and II molecules, and inhibit tumor angiogenesis (63-65). This angiogenesis *in vivo* can be suppressed by IFN- γ , which is produced by administration of IL-12 (63). It has been shown that TNF- α effectively stimulates not only IFN- γ production by human NK cells when combined with IL-1 β or IL-12 (66) but also tumor rejection due to the recruitment of NK cells into tumor or inflammatory sites (67,68). Although IL-10 did not induce the production of IFN- γ by NK cells, but it enhanced the ability of IL-18 to stimulate NK cell production of IFN- γ (69). Both IL-12 and IL-18 have been demonstrated to act synergistically to enhance *in vitro* antitumor capacity and IFN- γ production mediated *via* NK cells (70-73). Several studies have been reported that the antitumor effect that mediated by locally secreted IL-12 is augmented by systemic treatment with IL-18 (74), and that systemic administration of IL-18 alone results in not only suppression of tumor growth, but also increased survival rates of tumor-bearing mice (26,75-78). Furthermore, co-treatment of IL-18 with IL-10 stimulated NK cell proliferation, cytotoxicity, and IFN- γ production (69, 79,80). Flt 3L (fms-like tyrosine kinase 3 ligand) is also known to induce antitumor immune responses *in vivo* (81), and the expansion of DC, which promoted NK cell-dependent anti-tumor effects in mice with MHC class I-negative tumors (82). IFN- γ production and cytotoxic activity through activated murine NK cells are promoted by IL-21 and GM-CSF, but did not support their viability (83). Moreover, NK cell responses *via* IL-15-induced expansion of resting NK cells are restricted by IL-21, but promoted antigen-specific T cell activation. Thus, IL-21 prevented the initiation of further innate responses, indicating that it may be able to promote the transition from innate to adaptive immunity.

Meanwhile, NK cells secrete and respond to a number of chemokines including XCL1, CCL1, CCL3, CCL4, CCL5, CCL22, and CXCL8 (84), which are regulated, in part, by IL-15 (85-87), or IL-2 (88). These chemokines play an important role in NK cell homing to infected and neoplastic cells in secondary lymphoid tissues, where their production of IFN- γ may serve to directly regulate T cell responses (84). While resting CD56^{dim}/CD16⁺ NK cell subsets express CXCR1, CXCR2, CXCR3, and CXCR4, CD56^{bright}/CD16-NK cells express high levels of CCR5 and CCR7. Cytolytic activity of NK cells is stimulated by CCL2, CCL3, CCL4, CCL5, CCL10, and CXCL1.

NK cell cytotoxicity by granule exocytosis

Among NK cell-mediated target cell killing mechanisms, the release of cytoplasmic granules such as

perforin and granzymes (granule exocytosis) corresponds to the principal function (89). Most granule proteins are predominantly expressed in cytotoxic lymphocytes, including NK cells, CTLs, NKT cells and $\gamma\delta^+$ T cells. Perforin, a membrane-disrupting protein forms transmembrane pores in target cell membranes, and granzymes, a family of serine proteases, trigger apoptotic cell death either directly through caspase activation, or through caspase-independent pathways. Perforin-mediated killing appears to be promoted by IL-12-activated NK cells and mainly occurred in the lung and spleen, compared with the liver (90-92). NK activity and perforin expression were reduced in human immunodeficiency virus (HIV)-infected patients (93) and perforin expression was restored by *in vivo* administration of IFN- α . Both IL-12 and IL-21 induced the activation of NK cells, and suppression of various tumors in a perforin-dependent manner (72,94).

In the presence of perforin, synergistic effects of granzyme A and granzyme B on target cell death has been implicated to be triggered by nuclear damage (95). Recently, granzyme A and granzyme M that have been determined to induce caspase-independent cell death, and generate single stranded DNA nicks (96). In another molecule regarding granule exocytosis, granulysin known as a member of the saposin-like protein family including amoebapores and NK lysis has lytic activity against both microbes and tumors, but its precise mechanism in NK cell-mediated cytotoxicity remain to be further investigated (97-99).

NK cell cytotoxicity by death receptors

Expression of death receptors on target cell surface results in apoptosis signal *via* binding of a specific death ligand on NK cells in a caspase-dependent manner (100). The major family of death receptors is represented by TNF receptors (R), which consist of Fas (CD95, Apo-1), TNFR1 (p55, CD120a), TNF-R2 (p75, CD120b), death receptor 3 (DR3), death receptor 4 (DR4, TNF-related apoptosis inducing ligand (TRAIL)-R1) and death receptor 5 (DR5, TRAIL-R2). Since NK cells express members of TNF family ligands, NK cell-mediated apoptosis is dependent on the expression of caspases (101). RMA-S T lymphoma cells that do not normally express Fas, but it is upregulated directly by NK cells, and thereafter NK cells kill them in a Fas-dependent manner, indicating that death receptor-mediated apoptosis has a more prominent role in the clearance of NK-sensitive tumors (102). In particular, FasL expression on NK cells is shown to be involved in suppression of tumor metastases by IL-18 (103,104). Although activated NK cells expressing TRAIL that induced by IL-2, IFNs, or IL-15 represent a potent anti-tumorigenic effect (105), tumor initiation and meta-

stasis is augmented in TRAIL-deficient mice (106). Furthermore, TRAIL expression on NK cells is shown to eliminate immature DC *in vivo* and limit DC vaccination efficacy (107,108).

Concluding Remarks

In addition to the relation of NK cells with virus infection or tumor, NK cells are known to be involved in the pathogenesis of diseases such as asthma, graft-versus-host disease, Hodgkin's disease, and systemic lupus erythematosus, while they can selectively suppress the induction of some autoimmune diseases.

Despite the emerging role of NK cells as a powerful tool for tumor immunotherapy have been deciphering as a key linker between innate and adaptive immunity, the detailed mechanisms regarding the development or biological function of the different NK subsets is still unclear. Antigens derived from NK cell-mediated cytotoxicity against their targets stimulate DC maturation and activation, resulting in the enforcement of innate immunity followed by adaptive immunity through the triggering of subsequent T cell responses. IFN- γ -producing activated NK cells is also involved in the induction of antigen presentation by upregulating MHC class I and II molecules. As mentioned above, recent evidences indicate that the cross-talk of NK cells with DC plays a pivotal role in the triggering of adaptive immunity through the priming and/or stimulation of adaptive immune cells.

Tumor escape from NK cell attack might be derived from the dysregulation of adhesion molecules, co-stimulatory molecules, ligands for ITAM-bearing NK-cell receptors, and inflammatory/immunosuppressive cytokines on the NK cell or target cell. In NK cell-based tumor immunotherapy, the regulation of balance between inhibitory and activating receptor signaling and the discovery of the good candidates to augment both differentiation and effector function will be a powerful approach of clinical trials for tumor therapy. In addition, introducing immune responses inside tumor tissues is also capable of improvement of the NK-stimulating microenvironment.

Acknowledgements

This work was supported by a grant of the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (0420160-1).

References

1. Trincieri G: Biology of natural killer cells. *Adv Immunol* 47; 187-376, 1989
2. Robertson MJ, Ritz J: Biology and clinical relevance of human natural killer cells. *Blood* 76;2421-2438, 1990
3. Cooper MA, Fehniger TA, Caligiuri MA: The biology of human natural killer-cell subsets. *Trends Immunol* 22;633-640,

- 2001
4. Smyth MJ, Godfrey DI, Trapani JA: A fresh look at tumor immunosurveillance and immunotherapy. *Nat Immunol* 2; 293-299, 2001
5. Karre K, Ljunggren HG, Piontek G, Kiessling R: Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. *Nature* 319;675-678, 1986
6. Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC, Moretta L: Receptors for HLA class-I molecules in human natural killer cells. *Annu Rev Immunol* 14;619-648, 1996
7. Lanier LL: NK cell receptors. *Annu Rev Immunol* 16;359-394, 1998
8. Kelly JM, Darcy PK, Markby JL, Godfrey DI, Takeda K, Yagita H, Smyth MJ: Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. *Nat Immunol* 3;83-90, 2002
9. Shi FD, Wang HB, Li H, Hong S, Taniguchi M, Link H, Van Kaer L, Ljunggren HG: Natural killer cells determine the outcome of B cell-mediated autoimmunity. *Nat Immunol* 1;245-251, 2000
10. Kondo M, Scherer DC, King AG, Manz MG, Weissman IL: Lymphocyte development from hematopoietic stem cells. *Curr Opin Genet* 520-526, 2001
11. Lian RH, Kumar V: Murine natural killer cell progenitors and their requirements for development. *Semin Immunol* 14;453-460, 2002
12. Douagi I, Colucci F, Di Santo JP, Cumano A: Identification of the earliest prethymic bipotent T/NK progenitor in murine fetal liver. *Blood* 99;473-471, 2002
13. Williams NS, Klem J, Puzanov IJ, Sivakumar PV, Bennett M, Kumar V: Differentiation of NK1.1+, Ly49+ NK cells from flt3+ multipotent marrow progenitor cells. *J Immunol* 163; 2648-2656, 1999
14. Sivori S, Falco M, Marcenaro E, Parolini S, Biassoni R, Bottino C, Moretta L, Moretta A: Early expression of triggering receptors and regulatory role of 2B4 in human natural killer cell precursors undergoing in vitro differentiation. *Proc Natl Acad Sci USA* 99;4526-4531, 2002
15. Iizuka K, Chaplin DD, Wang Y, Wu Q, Pegg LE, Yokoyama WM, Fu YX: Requirement for membrane lymphotoxin in natural killer cell development. *Proc Natl Acad Sci USA* 96; 6336-6340, 1999
16. Briard D, Brouty-Boye D, Azzarone B, Jasmin C: Fibroblasts from human spleen regulate NK cell differentiation from blood CD34 (+) progenitors via cell surface IL-15. *J Immunol* 168;4326-4332, 2002
17. Williams NS, Kubota A, Bennett M, Kumar V, Takei F: Clonal analysis of NK cell development from bone marrow progenitors in vitro: orderly acquisition of receptor gene expression. *Eur J Immunol* 30;2074-2082, 2000
18. Wu Q, Sun Y, Wang J, Lin X, Wang Y, Pegg LE, Fütterer A, Pfeffer K, Fu YX: Signal via lymphotoxin-beta R on bone marrow stromal cells is required for an early checkpoint of NK cell development. *J Immunol* 166;1684-1689, 2001
19. Ogasawara K, Hida S, Azimi N, Tagaya Y, Sato T, Yokochi-Fukuda T, Waldmann TA, Taniguchi T, Taki S: Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. *Nature* 391;700-703, 1998
20. Suzuki H, Duncan GS, Takimoto H, Mak TW: Abnormal development of intestinal intraepithelial lymphocytes and peripheral NK cells in mice lacking the IL-2Rb chain. *J Exp Med* 185;499-505, 1997
21. Boggs SS, Trevisan M, Patrene K, Georgopoulos K: Lack of natural killer cell precursors in fetal liver of Ikaros knockout mutant mice. *Nat Immunol* 16;137-145, 1998
22. Colucci F, Samson SI, DeKoter RP, Lantz O, Singh H, Di Santo JP: Differential requirement for the transcription factor PU.1 in the generation of natural killer cells versus B and T cells. *Blood* 97;2625-2632, 2001
23. Ikawa T, Fujimoto S, Kawamoto H, Katsura Y, Yokota Y: Commitment to natural killer cells requires the helix-loop-helix inhibitor Id2. *Proc Natl Acad Sci USA* 98;5164-5169, 2001
24. Bar-Ner M, Messing LT, Segal S: Inhibition of murine erythroleukemia cell differentiation by normal and partially deleted c-myc genes. *Immunobiology* 185;150-158, 1992
25. Melotti P, Calabretta B: Induction of hematopoietic commitment and erythromyeloid differentiation in embryonal stem cells constitutively expressing c-myb. *Blood* 87;2221-2234, 1996
26. Wang Q, Yu H, Ju DW, He L, Pan JP, Xia DJ, Zhang LH, Cao X: Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma. *Gene Ther* Apr 8;542-550, 2001
27. Barton K, Muthusamy N, Fischer C, Ting CN, Walunas TL, Lanier LL, Leiden JM: The Ets-1 transcription factor is required for the development of natural killer cells in mice. *Immunity* 9;555-563, 1998
28. Colucci F, Rosmaraki E, Bregenholt S, Samson SI, Di Bartolo V, Turner M, Vanes L, Tybulewicz V, Di Santo JP: Functional dichotomy in natural killer cell signaling: Vav1-dependent and -independent mechanisms. *J Exp Med* 193; 1413-1424, 2001
29. Held W, Kunz B, Lowin-Kropf B, van de Wetering M, Clevers H: Clonal acquisition of the Ly49A NK cell receptor is dependent on the trans-acting factor TCF-1. *Immunity* 11;433-442, 1999
30. Held W, Clevers H, Grosschedl R: Redundant functions of TCF-1 and LEF-1 during T and NK cell development, but unique role of TCF-1 for Ly49 NK cell receptor acquisition. *Eur J Immunol* 33;1393-1398, 2003
31. Lacorazza HD, Miyazaki Y, Di Cristofano A, Deblasio A, Hedvat C, Zhang J, Cordon-Cardo C, Mao S, Pandolfi PP, Nimer SD: The ETS protein MEF plays a critical role in perforin gene expression and the development of natural killer and NK-T cells. *Immunity* 17;437-449, 2002
32. Lee KN, Kang HS, Jeon JH, Kim EM, Yoon SR, Song H, Lyu CY, Piao ZH, Kim SU, Han YH, Song SS, Lee YH, Song KS, Kim YM, Yu DY, Choi I: VDUP1 is required for the development of natural killer cells. *Immunity* (in press)
33. Wagtmann N, Rajagopalan S, Winter CC, Peruzzi M, Long EO: Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and by functional transfer. *Immunity* 3;801-809, 1995
34. Moretta A, Bottino C, Sivori S, Marcenaro E, Castriconi R, Della Chiesa M, Carlomagno S, Augugliaro R, Nanni M, Vitale M, Millo R: Natural killer lymphocytes: "null cells" no more. *Ital J Anat Embryol* 106;335-342, 2001
35. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA: Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. *Blood* 100;1935-1947, 2002
36. Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E, Augugliaro R, Moretta L, Moretta A: NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. *J Exp Med* 187;2065-2072, 1998
37. Smyth MJ, Hayakawa Y, Takeda K, Yagita H: New aspects of natural-killer-cell surveillance and therapy of cancer. *Nat Rev Cancer* 2;850-861, 2002
38. Diefenbach A, Raulet DH: The innate immune response to tumors and its role in the induction of T-cell immunity. *Immunol* 188;9-21, 2002
39. Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL,

- Phillips JH: An activating immunoreceptor complex formed by NKG2D and DAP10. *Science* 285; 730-732
40. Wu J, Cherwinski H, Spies T, Phillips JH, Lanier LL: DAP10 and DAP12 form distinct, but functionally cooperative, receptor complexes in natural killer cells. *J Exp Med* 192;1059-1068, 2000
 41. Lanier LL, Corliss BC, Wu J, Phillips JH: Association of DAP12 with activating CD94/NKG2C NK cell receptors. *Immunity* 8;693-701, 1998
 42. Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M, Chalupny NJ: ULBPs, novel MHC class-I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. *Immunity* 14;123-133, 2001
 43. Vales-Gomez M, Reyburn H, Mandelboim M, Strominger J: Kinetics of interaction of HLA-C ligands with killer cell inhibitory receptors with its biological implications. *Immunity* 9;337-344, 1998
 44. Liano M, Lee N, Navarro F: HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential responses to an HLA-G-derived nonamer. *Eur J Immunol* 28;2854-2863, 1998
 45. Vales-Gomez M, Reyburn HT, Erskine RA, Lopez-Botet M, Strominger JL: Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E. *EMBO J* 18; 4250-4260, 1999
 46. Wilson MJ, Torkar M, Trowsdale J: Genomic organization of a human killer cell inhibitory receptor gene. *Tissue Antigens* 49;574-579, 1997
 47. Bakker AB, Phillips JH, Figdor CG, Lanier LL: Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL. *J Immunol* 160; 5239-5245
 48. Le Dren E, Vely F, Olcese L, Cambiaggi A, Guia S, Krystal G, Gervois N, Moretta A, Jotereau F, Vivier E: Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases. *Eur J Immunol* 28; 264-276, 1998
 49. Takeda K, Oshima H, Hayakawa Y, Akiba H, Atsuta M, Kobata T, Kobayashi K, Ito M, Yagita H, Okumura K: CD27-Mediated Activation of Murine NK Cells. *J Immunol* 164;1741-1745, 2000
 50. Sugita K, Robertson MJ, Torimoto Y, Ritz J, Schlossman SF, Morimoto C: Participation of the CD27 antigen in the regulation of IL-2-activated human natural killer cells. *J Immunol* 149; 1199-1203, 1992
 51. Wilson JL, Charo J, Martin-Fontecha A, Dellabona P, Casorati G, Chambers BJ, Kiessling R, Bejarano MT, Ljunggren HG: NK cell triggering by the human costimulatory molecules CD80 and CD86. *J Immunol* 163;4207-4212, 1999
 52. Galea-Lauri J, Darling D, Gan SU, Krivochchapov L, Kuiper M, Gaken J, Souberbielle B, Farzaneh F: Expression of a variant of CD28 on a subpopulation of human NK cells: implications for B7-mediated stimulation of NK cells. *J Immunol* 163;62-70, 1999
 53. Lang S, Vujanovic NL, Wollenberg B, Whiteside TL: Absence of B7.1-CD28/CTLA-4-mediated co-stimulation in human NK cells. *Eur J Immunol* 28;780-786, 1998
 54. Martin-Fontecha A, Assarsson E, Carbone E, Karre K, Ljunggren HG: Triggering of Murine NK Cells by CD40 and CD86 (B7-2). *The Journal of Immunology* 162;5910-5916, 1999
 55. Nakajima A, Kodama T, Morimoto S, Azuma M, Takeda K, Oshima H, Yoshino S, Yagita H, Okumura K: Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7. *J Immunol* 161;1901-1907, 1998
 56. Sivori S, Parolini S, Falco M, Marcenaro E, Biassoni R, Bottino C, Moretta L, Moretta A: 2B4 functions as a co-receptor in human NK cell activation. *Eur J Immunol* 30;787-793, 2000
 57. Carson WE, Giri JG, Lindeman MJ, Linett ML, Ahdieh M, Anderson D, Eisenmann J, Grabstein K, Caligiuri MA: Interleukin-15 is a novel cytokine which activates human natural killer cells via components of the interleukin-2 receptor. *J Exp Med* 180; 1395-1403, 1994
 58. Carson WE, Fehniger TA, Haldar S, Eckhert K, Lindemann MJ, Lai C-F, Croce CM, Baumann H, Caligiuri MA: A potential role for interleukin-15 in the regulation of human natural killer cell survival. *J Clin Invest* 99;937-942, 1997
 59. Colombo MP, Trinchieri G: Interleukin-12 in anti-tumor immunity and immunotherapy. *Cytokine Growth Factor Rev* 13; 155-168, 2002
 60. Fehniger TA, Cooper MA, Caligiuri MA: Interleukin-2 and interleukin-15: immunotherapy for cancer. *Cytokine Growth Factor Rev* 13;169-183, 2002
 61. Perussia B: Lymphokine-activated killer cells, natural killer cells and cytokines. *Curr Opin Immunol* 3;49-55, 1991
 62. Loza MJ, Zamai L, Azzoni L, Rosati E, Perussia B: Expression of type 1 (interferon gamma) and type 2 (interleukin-13, interleukin-5) cytokines at distinct stages of natural killer cell differentiation from progenitor cells. *Blood* 99;1273-1281, 2002
 63. Yao L, Sgadari C, Furuke K, Bloom ET, Teruya-Feldstein J, Tosato G: Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. *Blood* 93;1612-1621, 1999
 64. Smyth MJ, Crowe NY, Pellicci DG, Kyparissoudis K, Kelly JM, Takeda K, Yagita H, Godfrey DI: Sequential production of interferon-gamma by NK1.1 (+) T cells and natural killer cells is essential for the antitumorigenic effect of alpha-galactosylceramide. *Blood* 99;1259-1266, 2002
 65. Hayakawa Y, Takeda K, Yagita H, Smyth MJ, Van Kaer L, Okumura K, Saiki I: IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide. *Blood* 100;1728-1733, 2002
 66. Cooper MA, Fehniger TA, Ponnappan A, Mehta V, Wewers MD, Caligiuri MA: Interleukin-1 β costimulates interferon gamma production by human natural killer cells. *Eur J Immunol* 31;792-801, 2001
 67. Smyth MJ, Kelly JM, Baxter AG, Korner H, Sedgwick JD: An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum. *J Exp Med* 188;1611-1619, 1998
 68. Pilaro AM, Taub DD, McCormick KL, Williams HM, Sayers TJ, Fogler WE, Wiltout RH: TNF-alpha is a principal cytokine involved in the recruitment of NK cells to liver parenchyma. *J Immunol* 153;333-342, 1994
 69. Cai G, Kanstein RA, Hunter CA: IL-10 enhances NK cell proliferation, cytotoxicity and production of IFN- γ when combined with IL-18. *Eur J Immunol* 29;2658-2663, 1999
 70. Leite-de-Moraes MC, Hameg A, Arnoud A, Machavoine F, Koezuka Y, Schneider E, Herbelin A, Dy M: A distinct IL-18-induced pathway to fully activate NKT lymphocytes independently from TCR engagement. *J Immunol* 163;5871-5880, 1999
 71. Hyodo Y, Matsui K, Hayashi N, Tsutsui T, Kashiwamura SI, Yamauchi H, Hiroishi K, Takeda K, Tagawa Y-I, Twakura Y, Kayagami N, Kurimoto M, Okamura H, Hada T, Yagita H, Akira S, Nakanishi K, Higashino K: IL-18 up-regulates perforin-mediated NK activity without increasing perforin messenger RNA expression by binding to constitutively expressed IL-18 receptor. *J Immunol* 162; 1662-1670, 1999
 72. Smyth MJ, Taniguchi M, Street SE: The antitumor activity of IL-12: mechanisms of innate immunity that are dose and mod-

- el dependent. *J Immunol* 165;2665-2670, 2000
73. Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M, Kawano S, Pelikan B, Crowe NY, Godfrey DI: Differential tumor surveillance by natural killer (NK) and NKT cells. *J Exp Med* 191;661-668, 2000
74. Nagai H, Hara Y, Horikawa T, Fujii M, Kurimoto M, Kamidono S, Ichihashi M: Antitumor effects on mouse melanoma elicited by local secretion of interleukin-12 and their enhancement by treatment with interleukin-18. *Cancer Invest* 18;206-211, 2000
75. Osaki T, Pero JM, Cai W, Okamura H, Robbins PD, Kurimoto M, Nagata S, Lotze MT, Tahara H: IFN- γ inducing factor/IL-18 administration mediated IFN- γ - and IL-12-independent antitumor effects. *J Immunol* 160;1742-1749, 1998
76. Micalleh MJ, Yoshida K, Kawai S, Hamaya T, Kohno K, Arai S, Tanimoto T, Torigoe K, Fujii M, Ikeda M, Kurimoto M: In vivo antitumor effects of murine interferon- γ inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites. *Cancer Immunol Immunother* 43; 361-367, 1997
77. Takeda K, Tsutsi H, Yoshimoto T, Adachi O, Yoshida N, Kishimoto T, Okamura H, Nakanishi K, Akira S: Defective NK cell activity and Th1 response in IL-18-deficient mice. *Immunity* 8;383-390, 1998
78. Ju DW, Yang Y, Tao Q, Song WG, He L, Chen G, Gu S, Ting CC, Cao X: Interleukin-18 gene transfer increases antitumor effects of suicide gene therapy through efficient induction of antitumor immunity. *Gene Ther* 19;1672-1680, 2000
79. Tripp CS, Wolf SE, Unanue ER: Interleukin-12 and tumor necrosis factor α are costimulators of interferon γ production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiological antagonist. *Proc Natl Acad Sci USA* 90;3725-3729, 1993
80. Hunter CA, Timans JC, Pisacane P, Menon S, Cai G, Walker W, Aste-Amezaga M, Chizzonite R, Bazan JF, Kastelein RA: Comparison of the effects of interleukin-1 α , interleukin-1 β and interferon- γ -inducing factor on the production of interferon- γ by natural killer. *Eur J Immunol* 27; 2787-2792, 1997
81. Lynch DH, Andreasen A, Maraskovsky E, Whitmore J, Miller RE, Schuh JC: Flt3 ligand induces tumor regression and antitumor immune responses in vivo. *Nature Med* 3;625-631, 1997
82. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E, Zitvogel L: Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. *Nature Med* 5;405-411, 1999
83. Kasaian MT, Whitters MJ, Carter LL, Lowe LD, Jussif JM, Deng B, Johnson KA, Witek JS, Senices M, Konz RF, Wurster AL, Donaldson DD, Collins M, Young DA, Grusby MJ: IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. *Immunity* 16;559-569, 2002
84. Robertson MJ: Role of chemokines in the biology of natural killer cells. *J Leukoc Biol* 71;173-183, 2002
85. Hanna J, Wald O, Goldman-Wohl D, Prus D, Markel G, Gazit R, Katz G, Haimov-Kochman R, Fujii N, Yagel S, Peled A, Mandelboim O: CXCL12 expression by invasive trophoblasts induces the specific migration of CD16 negative human natural killer cells. *Blood* 102;1569-1577, 2003
86. Barlic J, Sechler JM, Murphy PM: IL-15 and IL-2 oppositely regulate expression of the chemokine receptor CX3CR1. *Blood* 102;3494-3503, 2003
87. Dorner BG, Scheffold A, Rolph MS, Huser MB, Kaufmann SH, Radbruch A, Flesch IE, Kroczeck RA: MIP-1 α , MIP-1 β , RANTES, and ATAC/lymphotactin function together with IFN- γ as type 1 cytokines. *Proc Natl Acad Sci USA* 99;6181-6186, 2002
88. Beider K, Nagler A, Wald O, Franitz S, Dagan-Berger M, Wald H, Giladi H, Brocke S, Hanna J, Mandelboim O, Darash-Yahana M, Galun E, Peled A: Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NK T cells to the bone marrow and spleen of NOD/SCID mice. *Blood* 102;1951-1958, 2003
89. Trapani JA, Davis J, Sutton VR, Smyth MJ: Proapoptotic functions of cytotoxic lymphocyte granule constituents in vitro and in vivo. *Curr Opin Immunol* 12;323-329, 2000
90. Smyth MJ, Cretney E, Takeda K, Wiltout RH, Sedger LM, Kayagaki N, Yagita H, Okumura K: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. *J Exp Med* 193;661-670, 2001
91. Kodama T, Takeda K, Shimozato O, Hayakawa Y, Atsuta M, Kobayashi K, Ito M, Yagita H, Okumura K: Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12. *Eur J Immunol* 29;1390-1396, 1999
92. Brandau S, Suttman H, Riemensberger J, Seitzer U, Arnold J, Durek C, Jocham D, Flad HD, Bohle A: Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guerin-activated killer cells. *Clin Cancer Res* 6;3729-3738, 2000
93. Portales P, Reynes J, Rouzier-Panis R, Baillat V, Clot J, Corbeau P: Perforin expression in T cells and virological response to PEG-interferon alpha2b in HIV-1 infection. *AIDS* 17;505-511, 2003
94. Brady J, Hayakawa Y, Smyth MJ, Nutt SL: IL-21 induces the functional maturation of murine NK cells. *J Immunol* 172;2048-2058, 2004
95. Shi L, Kraut RP, Aebersold R, Greenberg AH: A natural killer cell granule protein that induces DNA fragmentation and apoptosis. *J Exp Med* 175;553-566, 1992
96. Kelly JM, Waterhouse NJ, Cretney E, Browne KA, Ellis S, Trapani JA, Smyth MJ: Granzyme M mediates a novel form of perforin-dependent cell death. *J Biol Chem* 279;22236-22242, 2004
97. Clayberger C, Krensky AM: Granzyme. *Curr Opin Immunol* 15;560-565, 2003
98. Gamon S, Anel A, Pineiro A, Naval J: Caspases are the main executioners of Fas-mediated apoptosis, irrespective of the ceramide signalling pathway. *Cell Death Differ* 5;241-249, 1998
99. Stenger S, Hanson DA, Teitelbaum R, Dewan P, Niazi KR, Froelich CJ, Ganz T, Thoma-Uzynski S, Melian A, Bogdan C, Porcelli SA, Bloom BR, Krensky AM, Modlin RL: An antimicrobial activity of cytolytic T cells mediated by granzyme. *Science* 282;121-125, 1998
100. Ashkenazi A, Dixit VM: Death receptors: signaling and modulation. *Science* 281; 1305-1308, 1998
101. Baker SJ, Reddy EP: Modulation of life and death by the TNF receptor superfamily. *Oncogene* 17;3261-3270, 1998
102. Screpanti V, Wallin RP, Ljunggren HG., Grandien A: A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells. *J Immunol* 167;2068-2073, 2001
103. Hashimoto W, Osaki T, Okamura H, Robbins PD, Kurimoto M, Nagata S: Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. *J Immunol* 163;583-589, 1999

104. Smyth MJ, Swann J, Kelly JM, Cretney E, Yokoyama WM, Diefenbach A, Sayers TJ, Hayakawa Y: NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer. *J Exp Med* 200;1325-1335, 2004
 105. Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, Iwakura Y, Yagita H, Okumura K: Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. *Nat Med* 7;94-100, 2001
 106. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ: Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. *J Immunol* 168;1356-1361, 2002
 107. Hayakawa Y, Screpanti V, Yagita H, Grandien A, Ljunggren HG, Smyth MJ, Chambers BJ: NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy. *J Immunol* 172;123-129, 2004
 108. Smyth MJ, Cretney E, Kelly JM, Westwood JA, Street SE, Yagita H, Takeda K, Dommelen SL, Degli-Esposti MA, Hayakawa Y: Activation of NK cell cytotoxicity. *Mol Immunol* 42;501-510, 2005
-